Investors

Corporate Profile
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in oncology with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.
Stock Information
AGLE (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.70
Change (%)0.00 (0.00%)
Volume12,568
Data as of 12/02/16 4:00 p.m. ET
Stock chart for: AGLE.O.  Currently trading at $5.70 with a 52 week high of $12.75 and a 52 week low of $3.89.

Recent NewsMore >>
11/21/16

Aeglea BioTherapeutics Announces Publication in Nature Medicine Demonstrating that Targeting Tumor Oxidative Stress with AEB3103 Suppresses Cancer Growth in Preclinical Models

AEB3103 Suppresses Tumor Growth by Depleting Serum Cystine and Inducing Reactive Oxygen Species AUSTIN, Texas, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-bas

Read More

11/09/16

Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results

AUSTIN, Texas, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat genetic rare diseases and cancer,

Read More

11/08/16

Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors

AUSTIN, Texas, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat genetic rare diseases and cancer,

Read More

Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.